Drug updated on 11/15/2023
|Tablet (oral; 200 mg)
|RAS GTPase inhibitors
|Ongoing and Completed Studies
- Indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.
Product Monograph / Prescribing Information
|Krazati (adagrasib) Prescribing Information.
|Mirati Therapeutics, Inc. 3545 Cray Court San Diego, CA
Systematic Reviews / Meta-Analyses
|Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis
|Expert review of anticancer therapy